ATE460431T1 - Nicht-neutralisierende anti-apc-antikörper - Google Patents

Nicht-neutralisierende anti-apc-antikörper

Info

Publication number
ATE460431T1
ATE460431T1 AT03741459T AT03741459T ATE460431T1 AT E460431 T1 ATE460431 T1 AT E460431T1 AT 03741459 T AT03741459 T AT 03741459T AT 03741459 T AT03741459 T AT 03741459T AT E460431 T1 ATE460431 T1 AT E460431T1
Authority
AT
Austria
Prior art keywords
apc
antibodies
present
activity
inactivation
Prior art date
Application number
AT03741459T
Other languages
English (en)
Inventor
Takaki Koga
Tsukasa Suzuki
Hiroyuki Saito
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30767813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE460431(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE460431T1 publication Critical patent/ATE460431T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03741459T 2002-07-22 2003-07-17 Nicht-neutralisierende anti-apc-antikörper ATE460431T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002212582 2002-07-22
PCT/JP2003/009087 WO2004009641A1 (ja) 2002-07-22 2003-07-17 aPC非中和抗体

Publications (1)

Publication Number Publication Date
ATE460431T1 true ATE460431T1 (de) 2010-03-15

Family

ID=30767813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03741459T ATE460431T1 (de) 2002-07-22 2003-07-17 Nicht-neutralisierende anti-apc-antikörper

Country Status (9)

Country Link
US (1) US7517965B2 (de)
EP (1) EP1544214B1 (de)
JP (1) JP4398369B2 (de)
AT (1) ATE460431T1 (de)
AU (1) AU2003281619A1 (de)
DE (1) DE60331665D1 (de)
ES (1) ES2340842T3 (de)
TW (1) TW200407335A (de)
WO (1) WO2004009641A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007101362A (ja) * 2005-10-04 2007-04-19 Hamamatsu Univ School Of Medicine Ｅｉａプレート及びその利用方法
IN2014DN10515A (de) * 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
DK3059246T3 (en) * 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
AU2008323947B2 (en) * 2007-11-06 2014-02-20 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
EP2409991B1 (de) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
EP2421900A1 (de) 2009-04-24 2012-02-29 Alper Biotech, Llc Monoklonale antikörper gegen pcbp-1-antigene, und anwendungen davon
EP2596365A4 (de) 2010-07-14 2013-12-18 Alper Biotech Llc Monoklonale antikörper gegen pcbp1-antigene und anwendungen davon
KR20150088853A (ko) * 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
TWI673063B (zh) * 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白ｃ抗體之出血性疾病的治療
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP4062933A4 (de) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antikörperhaltiges präparat
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11A (de) * 1836-08-10
US1222929A (en) * 1916-08-22 1917-04-17 Brewster & Co Brake mechanism for motor-cars.
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
GB8327860D0 (en) 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3882411T2 (de) * 1987-04-17 1993-12-16 Teijin Ltd Verfahren zur Trennung von aktiviertem menschlichem Protein C.
CA2006684C (en) * 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
JP2749619B2 (ja) * 1989-03-10 1998-05-13 エーザイ株式会社 活性化ヒトプロテインｃとヒトプロテインｃインヒビターの複合体の測定方法および測定試薬
JPH03200066A (ja) * 1989-12-28 1991-09-02 Tosoh Corp 活性化ヒトプロテインｃの測定方法
US5279956A (en) 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser
ATE410514T1 (de) 1994-06-10 2008-10-15 Oklahoma Med Res Found Calciumbindende rekombinante antikörper gegen protein c
JPH1160500A (ja) 1997-08-11 1999-03-02 Nippon Chem Res Kk 血液凝固異常亢進抑制剤
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
JPH11124399A (ja) 1997-10-21 1999-05-11 Eisai Co Ltd プロテインｃインヒビターとプロテアーゼの複合体測定用モノクローナル抗体
SE9900431D0 (sv) 1999-02-09 1999-02-09 Johan Stenflo Monoklonal antikropp
ES2346189T3 (es) 2001-01-11 2010-10-13 Life Sciences Research Partners Vzw Metodo y composicion farmaceutica para prevenir y/o tratar el sindrome de respuesta inflamatoria generalizada.
JPWO2004065418A1 (ja) * 2003-01-20 2006-06-29 中外製薬株式会社 抗ｐｃｉ中和抗体

Also Published As

Publication number Publication date
US20060121022A1 (en) 2006-06-08
TW200407335A (en) 2004-05-16
JP4398369B2 (ja) 2010-01-13
WO2004009641A1 (ja) 2004-01-29
AU2003281619A1 (en) 2004-02-09
DE60331665D1 (de) 2010-04-22
TWI322814B (de) 2010-04-01
EP1544214A4 (de) 2007-03-28
JPWO2004009641A1 (ja) 2005-11-17
ES2340842T3 (es) 2010-06-10
US7517965B2 (en) 2009-04-14
EP1544214B1 (de) 2010-03-10
EP1544214A1 (de) 2005-06-22

Similar Documents

Publication Publication Date Title
DE60331665D1 (de) Nicht-neutralisierende anti-apc-antikörper
CY1116215T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
DE60108076D1 (de) Protein c derivate
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
BR0112123A (pt) Composto
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE402147T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties